Replies to post #2030 on Tauriga Sciences Inc (fka TAUG)

[calsurfer]

Blackcat--sorry about the link but this is good news!

QUOTE FROM ARTICLE: "This is the first report of significantly prolonged survival following a diagnosis of grade III/stage III bronchoalveolar adenocarcinoma in a canine patient."

ITL is closed for Shabbat today so no one answers the phone. However, I called the journal and they apparently closed access because too many hits! They said I can get a PDF version from one of the authors. However, they sent the abstract to me which I cut and pasted below. (I do not have Dr Har-Noy's direct email, only the 'info' email at ITL from the website which he answers).

THIS IS GREAT NEWS THAT ANOTHER ITL PRODUCT HAS BEEN SHOWN TO EXTEND THE LIFE OF A DOG WITH CANCER FROM 6 WEEKS TO 50+ WEEKS. IMAGINE WHAT IT COULD DO FOR HUMANS! The full paper has CT scan images and immunology data using blots to support that CRCL vaccination had an immune response to the tumor which extended the survival.

ITL told me yesterday that this CRCL product is approved for a Phase I/II trial of head and neck cancers in humans.

Here is the abstract for dogs by the University of Colorado (Dr Har-Noy is also an author):

TITLE
Prolonged remission of advanced bronchoalveolar adenocarcinoma in a dog treated with autologous, tumour-derived chaperone-rich cell lysate (CRCL) vaccine

AUTHORS
Laura M. Epple, Lynne T. Bemis, Ryan P. Cavanaugh, Anne Skope, Tehila Mayer-Sonnenfeld, Chad Frank, Christine S. Olver, Alex M. Lencioni, Nathaniel L. Dusto, Alona Tal, Michael Har-Noy, Kevin O. Lillehei,Emmanuel Katsanis and Michael W. Graner

ABSTRACT
Purpose: This paper presents the treatment of a 12-year-old female spayed Great Dane who presented with vestibular signs (ataxia, nystagmus, hind end collapse). Thoracic radiographs
revealed a discrete pulmonary nodule in the right cranial lung lobe. Ultrasound-guided fine needle aspirate detected primary bronchoalveolar adenocarcinoma, verified via computed tomography , with a second smaller nodule discovered in the right cranial lung lobe.

Materials and methods: A lateral thoracotomy with right cranial lung lobectomy was performed. Histopathological analysis of the nodules and an excised lymph node identified grade III
bronchoalveolar adenocarcinoma with vascular infiltration and lymph node metastasis – a grim diagnosis with a reported median survival time of 6–27 days. A 10-g sample of the tumour was
processed into a chaperone-rich cell lysate (CRCL) vaccine, which was administered weekly to the patient. Imiquimod – a Toll-like receptor 7 (TLR7) agonist – was applied topically for the first
12 treatments to stimulate local Langerhans cells. A single injection of bacillus Calmette-Guerin (BCG) was administered for additional immune stimulation at week 30 of treatment.

Results: The dog remained stable and in otherwise good health until diffuse relapse occurred 44 weeks after the initial treatment; following gastrointestinal bleeding, the dog was euthanized 50+ weeks post diagnosis.

Conclusion: To the authors’ knowledge, this is the first report of significantly prolonged survival following a diagnosis of grade III/stage III bronchoalveolar adenocarcinoma in a canine patient. This case report suggests that CRCL vaccine combined with topical imiquimod is a safe, treatment for canine tumours.

ITL has assets of significant potential value. We should support ITL in anyway possible to enhance our 9% position.